Skip to content
Biotech Intelligence

Intelligence Briefing

Biotech Intelligence #6: The NewCo Model — Why Chinese Biotechs Are Creating New Companies Instead of Licensing

A new deal structure is emerging: Chinese biotechs creating Western-capitalized NewCos to develop their assets ex-China, instead of traditional out-licensing. We analyze the model, track the first examples, and explain why this changes the competitive dynamics for BD teams.

By Antony Tan4 min read
LicensingOncologyADCBIOSECURECDE Filing

This Week's Top Takeaway

The "NewCo" licensing model is the most significant structural innovation in China-to-West deal-making since the multi-asset framework. Instead of licensing assets to an existing Big Pharma, Chinese biotechs are creating new companies — capitalized by Western VCs and institutional investors — to develop their assets ex-China. The Chinese licensor retains more economic upside (equity + royalties vs. milestones only), and Western investors get direct equity exposure to Chinese innovation without the governance complexity of investing in China-listed entities.

BIOSECURE Watch

Status: 🟡 Monitoring
  • SEC BIOSECURE disclosures: approximately 8 companies have filed. Convergence on standard risk factor language continues.
  • OMB: no public activity on BCC list process
  • Congressional: no new developments on WuXi 1260H recommendation
  • WuXi AppTec (药明康德): Q4 2025 earnings call expected next week — analysts will probe BIOSECURE contingency planning and client retention
One development worth tracking: The NewCo model (described above) may have BIOSECURE implications. If a Chinese company creates a US-incorporated NewCo that contracts with WuXi for manufacturing, the BIOSECURE restriction applies to the NewCo's federal contracting — not the Chinese parent's. This adds a layer of structural complexity to compliance analysis.

CDE Filing Watch

  • Hengrui (恒瑞医药) filed a Phase II protocol amendment for HRS-9821 (PDE3/4 inhibitor, the lead asset in the GSK deal). The amendment expands the patient population — consistent with GSK's strategy to position this asset across the widest spectrum of COPD patients.
  • BeiGene (百济神州) received CDE approval for a new zanubrutinib combination regimen in mantle cell lymphoma. BeiGene continues to expand the zanubrutinib label through CDE before pursuing parallel FDA approvals — a strategy that generates Chinese clinical data faster and cheaper than US-first development.

Takeaways for BD Teams

  1. If you're only offering traditional licenses, you're competing against NewCos offering equity. Chinese biotechs with high-value assets increasingly prefer the NewCo economics. Adjust your deal structures or lose to the VC-backed alternative.
  1. The NewCo model creates new competitors. A Western-capitalized NewCo with a licensed Chinese asset is a new entrant in your therapeutic area — and it has VC backing, focused management, and a motivated Chinese partner. Track these entities as competitive threats, not just deal structures.
  1. BIOSECURE applies to NewCos too. A US-incorporated entity that contracts with designated BCCs faces the same restrictions as any other federal contractor. The NewCo structure doesn't create a BIOSECURE safe harbor.
  1. Watch BeiGene's CDE-first, FDA-second strategy. Generating Chinese clinical data before pursuing US registration is becoming the standard playbook. BD teams should be monitoring CDE trial registrations 12-18 months before US IND filings — that's your scouting window.
Biotech Intelligence is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan